AWCT key facts
as of Oct 2026- Developer of healthcare technology intended to restructure the treatment of diseases and disorders without drugs, implants, or surgery.
- AWCT is valued at approximately $30.0M as of Oct 2026 (last reported valuation).
- It has raised $20.5M; the latest was Later Stage VC in Jun 2025.
- Notable investors include WI Harper Group, Taiwania Capital.
- Status: Privately Held (backing).
AWCT's last reported valuation, Nov 2023. Nothing priced has surfaced since.
- ·Watch AWCT: the Monday email on marks, rounds and moves
AWCT funding rounds
No funding rounds for AWCT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs AWCT
2AWCT valuation
AWCT's last reported valuation was $30 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.
AWCT investors
2 investors are on record for AWCT, including WI Harper Group and Taiwania Capital.
About AWCT
Developer of healthcare technology intended to restructure the treatment of diseases and disorders without drugs, implants, or surgery. The company's technology activates innate repair mechanisms in tissue to replace cells and repair damage from wounds and disease, enabling doctors to match the effectiveness of surgery with a non-invasive, minimal-risk treatment.
- Sector
- Healthcare
- HQ
- Los Angeles, CA, United States
- Founded
- 2014
- Employees
- 9
- Website
- awct.us/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.